Tevimbra: Expiry of patents in US/EU/China/Japan related to composition-of-matter in 2033 (BeOne Medicines) - Mar 23, 2026 - Annual Report 2025: Patent term extension in US/EU until 2038; Expiry of patents in US related to method of treatment in 2039
Patent • Bladder Cancer • Colorectal Cancer • Endometrial Cancer • Esophageal Cancer • Esophageal Squamous Cell Carcinoma • Gastric Adenocarcinoma • Gastric Cancer • Gastroesophageal Cancer • Gastroesophageal Junction Adenocarcinoma • Gastrointestinal Cancer • Genito-urinary Cancer • Gynecologic Cancers • Head and Neck Cancer • Hematological Malignancies • Hepatocellular Cancer • Hodgkin Lymphoma • Liver Cancer • Lung Cancer • Lung Non-Small Cell Squamous Cancer • Lung Non-Squamous Non-Small Cell Cancer • Lymphoma • Microsatellite Instability • Nasopharyngeal Carcinoma • Neuroendocrine Neoplasm • Neuroendocrine Tumor • Non Small Cell Lung Cancer • Oncology • Small Cell Lung Cancer • Solid Tumor • Squamous Cell Carcinoma • Thoracic Cancer • Urothelial Cancer • Uterine Cancer
|